When human umbilical vein endothelial cultures were grown in the presence of supplemental arachidonic acid, the cell phospholipids became enriched with arachidonic acid. Prostacyclin (PGI 2 ) accumulated in the medium during supplementation with arachidonic acid. The capacity of these enriched cultures to produce PGI 2 when subsequently incubated with either arachidonic acid or thrombin was reduced by as much as 90%, but release of arachidonic acid from the cell lipids in response to thrombin stimulation was not inhibited. Refractory cultures completely recovered the capacity to form PGI 2 within 18 hours after removal of the medium containing supplemental arachidonic acid. However, recovery was prevented by cycloheximide. When enrichment with arachidonic acid was done in the presence of ibuprofen, a reversible cyclooxygenase inhibitor, PGI 2 did not accumulate in the medium during supplementation, and the subsequent capacity of the cultures to produce PGI 2 in response to thrombin increased by 70% to 240%. By contrast, the capacity of these supplemented cultures to convert added arachidonic acid to PGI 2 did not increase. Therefore, the enhancement in thrombin-stimulated PGI 2 production when the cultures are supplemented with arachidonic acid probably is due to the larger amount of arachidonic acid available in the intracellular lipid substrate pools, rather than to an activation of the PGI 2 synthetic pathway. These findings suggest that changes in the arachidonic acid content of the endothelial cell lipids may modulate the capacity of the endothelium to produce PGI 2 in response to stimulation. (Arteriosclerosis 3:323-331, July/August 1983) E ndothelial cells produce prostacyclin (PGI 2 ), a prostaglandin that is a vasodilator and inhibitor of platelet aggregation. 12 These effects are thought to protect against ischemia and thrombosis. 3 Because of this, we attempted to develop a means of enhancing the capacity of endothelial cells to produce PGI 2 in response to stimulation. This was done by supplementing the cells with linoleic acid, the rationale be-From the
ing that this would enrich the intracellular substrate pools with arachidonic acid, the precursor of PGI 2 . 4 ' 5 The approach seemed reasonable because previous work demonstrated that enrichment of 3T3 cells with linoleic acid leads to an accumulation of arachidonic acid and an increase in prostaglandin production. 6 It was found, however, that cultured endothelial cells were not able to convert linoleic to arachidonic acid. 78 Supplementation with linoleic acid actually reduced the arachidonic acid content of the endothelial cell phospholipids, leading to a decrease in PGI 2 production. 8 " 10 In the course of the work, we observed that the endothelial cells took up large amounts of arachidonic acid from the extracellular fluid and incorporated much of it into phospholipids. 78 Therefore, we investigated whether the capacity of the endothelial cells to produce PGI 2 might be enhanced by enrichment in this way with arachidonic acid.
Methods

Endothellal Cell Cultures
Endothelial cells were obtained from human umbilical veins, 11 and primary cultures were prepared according to a slight modification of the method of Jaffe et al. 12 as previously described. 7 Briefly, the cells were suspended in a modified medium 199 containing 20% heat-inactivated fetal bovine serum, counted with a hemocytometer, and seeded in 25cm 2 flasks at a concentration of 2.25 x 10 6 cells per flask. After incubation for 24 hours at 37°C in a atmosphere of 5% CO 2 , this medium was replaced with 3 ml of medium 199 containing 25 mM Hepes plus 20% fetal bovine serum, and the confluent cultures were continued in the 5% CO 2 atmosphere.
Preparation of Fatty Acid-Supplemented Media
Fatty acids were purchased from Nu Chek Prep (Elysian, Minnesota) and were more than 99% pure as determined by gas-liquid chromatography. We obtained 1 J4 C-arachidonic acid from New England Nuclear (Boston, Massachusetts) and periodically checked it for purity by thin-layer and gas-liquid chromatography. The culture media contained medium 199,25 mM Hepes, 2.5% fetal bovine serum, and 90 /xM bovine serum albumin, Fraction V, fatty acid-free (Miles Laboratories, Elkhart, Indiana). Media were enriched with fatty acids by adding the sodium salt. 7 The media were then adjusted to pH 7.4 at 37°C and sterilized by filtration through a 0.22 /i filter. Before supplementation, the serum contained 0.29 /u.mol/ml of free fatty acid, about 10% of this being arachidonic acid. Free fatty acid concentration was measured colorimetrically, 13 and individual fatty acids were determined by gas-liquid chromatography. 9
Incubation and Llpid Analysis
The maintenance medium was removed, and the endothelial cell monolayers were washed twice with 2.5 ml of a buffer solution containing 137 mM NaCI, 5 mM KCI, 8 mM Na 2 HPO 4 , and 2 mM KH 2 PO 4 (pH 7.4). After addition of 2.5 ml of the fatty acid-supplemented medium, the incubations were carried out at 37°C with a 5% CO 2 atmosphere. The incubations were terminated by aspirating the medium, followed by washing the monolayer twice with 2 ml of ice-cold buffer solution. After harvesting by scraping, the cells were suspended in the cold buffer, sedimented at 600 gfor 10 minutes at 4°C, and suspended in 1 ml of fresh cold buffer. Previous studies with radioactive arachidonic and stearic acids indicated that this scraping procedure did not cause an excessive hydrolysis of fatty acids from phospholipids, as compared with other currently available methods for cell harvesting. 7 A portion of the suspension was removed for determination of the cell protein content. 14 The remainder of the suspension was extracted with 20 volumes of a mixture of chloroform and methanol (2:1, vol/vol) in order to isolate the lipids. 15 Following separation and isolation of the chloroform phase, the solvent was evaporated under N 2 , and the lipid residue was dissolved in a measured volume of fresh chloroform.
Separation of phospholipids and neutral lipids was obtained by thin-layer chromatography on silica gel G with a solvent system containing hexane-diethyl ether-acetic acid-methanol (170:40:4:4). Standards obtained from Nu Chek Prep were added to each chromatogram, and the lipids were visualized by exposure to l 2 vapor. After sublimation, the outlined segments of silica gel were scraped into liquid scintillation counting vials.
Phospholipids were separated by thin-layer chromatography on silica gel H using a modification of the method of Skipski et al. 16 This modification, which separates the inositol and serine phosphoglycerides, uses a solvent system containing chloroform-methanol-acetic acid-water (100:50:16:8). The R, values for the major phospholipid classes in these chromatograms were: lysophosphatidylcholine, 0.08; sphingomyelin, 0.22; phosphatidylcholine, 0.40; phosphatidylinositol, 0.65; phosphatidylserine, 0.72; phosphatidylethanolamine, 0.90.
Fatty acids were isolated from the various lipid classes by saponification, acidification, and extraction into hexane. 17 After methylation with 14% BF 3 in methanol, 18 the fatty acid methyl esters were extracted into hexane and separated by gas-liquid chromatography. 17 Separation was achieved using a 2 mm x 1.9-m glass column packed with 10% SP2330 on 100/120 mesh Chromosorb W-AW (Supelco, Incorporated, Bellefonte, Pennsylvania). The Hewlett-Packard model 5700 gas chromatograph (Hewlett-Packard Company, Palo Alto, California) was equipped with a 9:1 stream splitter so that a portion of the effluent could be collected when radiolabeled material was chromatographed. A flame ionization detector was used. N 2 served as the carrier gas at a flow rate of 25 ml/min, and the oven temperature was programmed from 176° to 220°C. Peak areas were determined with a Hewlett-Packard model 3380S integrator-recorder, and the areas are reported as weight percentages.
Radioactivity was measured in a liquid scintillation spectrometer using counting vials containing 10 ml of Budget Solve scintillator solution (Research Products International, Elk Grove Village, Illinois). Quenching was monitored with a 226 Ra external standard.
PGI 2 Assay
After the experimental medium was removed, the monolayer of intact, confluent endothelial cells (3.5 x 10 5 cells in a 25 x 10 mm culture dish) was washed with a buffer solution warmed to 37°C. This solution contained 140 mM NaCI, 6 mM KCI, 3 mM CaCI 2 and 16 mM Tris-HCI adjusted to pH 7.4. The cultures then were washed with a second solution containing 0.125 mM bovine serum albumin, fatty acid-free, plus the above salts and buffer. A fairly high concentration of albumin was included in this wash in an attempt to remove any free fatty acid that remained attached to the cells, a precaution that was considered especially important when the incubation medium contained supplemental fatty acids. Following this washing procedure, the monolayers were incubated for 5 minutes at 37°C with 0.6 ml of either this solution as a control, or this solution containing 1 U/ml of bovine thrombin. The medium was removed from the cultures, and PGI 2 release was measured in the supernatant solution by a radioimmunoassay for the 6-keto-derivative of prostaglandin F 1a (6-keto-PGF la ), a stable catabolic product of PGI 2 .
The radioimmunoassay was performed using an antiserum against 6-keto-PGF 1a . 100 /AI of either standard or samples was mixed with 100 /xl of 3 H-6keto-PGF 1(I (New England Nuclear, Boston, Massachusetts) and 10 fi\ antiserum at a dilution that bound 50% of the radioactivity in the absence of standard. After 1 hour of incubation at 37°C, 50 pil IgGsorb (The Enzyme Center Incorporated, Tufts University School of Medicine, Boston, Massachusetts) was added, and the radioactivity contained in a 100 n\ sample of the supernatant solution was measured in a liquid scintillation spectrometer. Assay detection limits were 0.3 pmol of 6-keto-PGF 1o , and 50% inhibition was obtained with 3.3 pmol of 6-keto PGF la . This assay 20 has negligibly small amounts of cross-reactivity with prostaglandins other than 6-keto-PGF, Q .
Formation of Radioactive Prostaglandins
Endothelial cell monolayers were incubated for 5 minutes at 37°C with a 2.5 ml of medium containing 8.75 nmol of 1-14 C-arachidonic acid (New England Nuclear, 55 Ci/mol), 140 mM NaCI, 5.8 mM KCI, 2.7 mM CaCI 2 , 1.1 mM N^CC^, and 16.3 mM Tris HCI adjusted to pH 7.4. Corresponding control incubations were done in empty dishes. After incubation, the medium was removed quantitatively, acidified to pH 3.5 with 1 M citric acid, and extracted twice with 2 volumes of ethyl acetate after addition of NaCI. 21 Aliquots of the ethyl acetate extract were chromotographed with the organic phase of a mixture containing ethyl acetate-acetic acid-2,2,4-trimethyl pentane-H 2 O (11O:2O:5O:1OO). 5 After staining with I 2 vapor and sublimation, the radioactivity contained in the outlined segments of silica gel was measured in a liquid scintillation spectrometer. In the empty dish controls, an average of only 0.45% of the added arachidonic acid radioactivity migrated in the region of the 6-ketoPGF la standard. This small amount of background radioactivity was subtracted from the quantity recovered in the 6-keto-PGF 1a region of the chromatograms from the incubations with endothelial cell monolayers.
Results
PGI 2 Production
Human umbilical vein endothelial cultures were incubated for 24 hours with a medium containing supplemental arachidonic acid. After this period of enrichment, the media were removed, the cultures washed, and PGI 2 production was subsequently measured during a 5-minute period of stimulation with thrombin. Every experiment was done with a different primary endothelial cell culture, and each culture produced a somewhat different absolute amount of PGI 2 in response to thrombin stimulation. As shown in the top panel of Figure 1 , a 50% reduction in thrombin-stimulated PGI 2 release occurred in cultures that had been previously supplemented for 24 hours with 20 /iM arachidonic acid. In these studies the culture medium contained 2. salt solution containing 1 U/ml thrombin was added for 5 minutes. The release of PGI 2 was measured by radioimmunoassay as 6-keto-PGF lQ . Inhibition of PGI 2 production increased to 90% when the arachidonic acid concentration was raised to 150 fxM. The time-dependence of the inhibition is seen in the lower panel of Figure 1 . A 65% reduction in subsequent thrombin-stimulated PGI 2 release occurred when the cultures were supplemented with 50 nM arachidonic acid for only 30 minutes. The reduction increased to 85% when the supplementation period was extended to 2.5 hours and then remained at this level. The capacity of the cultures to produce PGI 2 following arachidonic acid enrichment also was tested in response to a subsequent 5-minute incubation with additional arachidonic acid. One set of cultures was initially exposed to a medium containing 2.5% fetal bovine serum, 90 /xM albumin and 100 //.M arachidonic acid. The other set was incubated with a similar medium containing no supplemental arachidonic acid. After 24 hours, these media were removed and the cultures washed. A solution containing 0 to 450 nM arachidonic acid and 90 /iM albumin was added for 5 minutes, and the amount of PGI 2 produced was measured by radioimmunoassay as 6-keto-PGF la . Figure 2 shows the amount of 6-keto-PGF 1a formed relative to the concentration of arachi- donic acid added during the final 5-minute incubation. Only small amounts of PGI 2 were produced by the cultures that had been supplemented with arachidonic acid during the previous 24 hours. By contrast, large amounts of PGI 2 were released by corresponding control cultures not previously exposed to supplemental arachidonic acid, the release increasing as the arachidonic acid concentration in the test medium was raised. In a similar experiment, 1-14 Carachidonic acid was added during the 5-minute assay period, and the distribution of radioactivity in the various prostaglandins was determined following separation by thin-layer chromatography. 6 Most of the prostaglandin radioactivity was recovered in three bands. In the unsupplemented control cultures, 70% of the radioactivity converted to prostaglandins was in a band that cochromatographed with 6-keto-PGF la , 15% in a band that migrated with prostaglandin E 2 (PGE 2 ) and 15% in a band that migrated with prostaglandin F 2a (PGF^). The quantity of radioactivity contained in each band was reduced considerably in those cultures that were initially supplemented with arachidonic acid. The percentage reductions were 85% in 6-keto-PGF, a , 50% in PGE 2 , and 75% in PGF^.
The endothelial cultures produced large amounts of PGI 2 during the time that they were being supplemented with arachidonic acid if the medium containing 2.5% fetal bovine serum and 90 /^M albumin did not contain a cyclooxygenase inhibitor. As shown in Figure 3 , much of the PGI 2 production measured by radioimmunoassay as 6-keto-PGF, ( the first 0.5 hour of supplementation with 100 arachidonic acid. By contrast, very little PGI 2 was produced if the culture medium was not supplemented with arachidonic acid or if 200 fiM ibuprofen, a reversible cyclooxygenase inhibitor, 22 ' a was added to the medium containing supplemental arachidonic acid.
Enrichment with Arachidonic Acid
To determine whether cultures supplemented and washed as described in Figures 1-3 actually became enriched with arachidonic acid, we carried out isotopic and chromatographic studies on the cell lipids. The results of the incorporation of 1-u C-arachidonic acid are shown in Table 1 . Endothelial cell cultures were incubated for 2 hours with 50 [xM 1-14 C-arachidonic acid plus 90 yu.M albumin, and the incorporations in nmol amounts were calculated from the specific radioactivity of the arachidonic acid added to the medium. The highest incorporations were into triglycerides, choline phosphoglycerides, and inositol phosphoglycerides. The effect of ibuprofen on 1 -14 C-arachidonic acid uptake also was examined. Although statistically significant reductions in the amounts of arachidonic acid incorporated into the ethanolamine and inositol phosphoglyceride fractions occurred when 100 fxM ibuprofen was added, the magnitude of these reductions was quite small.
The time dependence of 1-l4 C-arachidonic acid uptake was examined during a 4-hour incubation. Total arachidonic acid uptake was roughly linear over the first 2 hours and then decreased somewhat. Incorporation into triglycerides remained linear over the entire 4-hour period. By contrast, incorporation into the diglyceride and free fatty acid fractions reached a maximum by 1 hour and did not change appreciably thereafter. Incorporation into total phospholipids was linear for 2 hours and then continued at a slower rate. After 30 minutes the inositol phosphoglycerides contained 25% more radioactivity than the choline phosphoglycerides. Further accumulation of arachidonic acid radioactivity occurred at a faster rate in the choline phosphoglycerides than in the other phospholipids, and this fraction contained more radioactivity than any of the other phospholipid fractions during the remainder of the 4-hour incubation.
Supplementation of the culture medium with arachidonic acid produced changes in the fatty acid composition of the endothelial cell phospholipids. Table 2 contains the results of an experiment in which the cultures were incubated for 24 hours in a medium containing 2.5% fetal bovine serum, 90 nM albumin and with either no supplemental fatty acid, 50 /xM arachidonic acid, or 50 /xM arachidonic acid plus 50 /J.M ibuprofen. When the medium was supplemented with arachidonic acid, there was a 70% increase in the arachidonic acid (204) content of the cell phospholipids. There also was a large increase in the adrenic acid (22:4) content, and these increases were accompanied by decreases primarily in palmitic (16.0) and oleic (18-1) acids. The presence of ibuprofen in the culture medium did not appreciably influence the changes in phospholipid fatty acid composition produced when the medium was supplemented with arachidonic acid. Based upon these results, it is clear that the failure of the supplementation procedure to enhance PGI 2 production is not due to an inability to enrich the cell phospholipids with arachidonic acid.
Release of Cellular Arachidonic Acid
Experiments were done to determine whether cultures enriched with arachidonic acid were able to release this fatty acid in response to thrombin stimulation. Control cultures were incubated in a medium containing 2.5% fetal bovine serum and 90 nM albumin for 2 hours. Corresponding cultures were incubated in this medium supplemented with 100 /xM arachidonic acid. As shown in Figure 1 , a 2-hour tSince the results for a number of the fatty acids that accounted for 2% or less of the total have been omitted, the values do not add up to 100%. Each value is the mean ± SE of four separate cultures. supplementation with arachidonic acid reduced thrombin-stimulated PGI 2 production by almost 75%. After the supplementation media were removed and the cultures washed, both sets were incubated for 30 minutes with 4.7 x 10 5 dpm of 1-14 C-arachidonic acid. All the cultures incorporated similar amounts of radioactivity into cell lipids, 1.6 ± 0.07 x 10 5 dpm. The cultures were washed with a solution containing albumin to remove any cellular radioactive free fatty acid. Each culture then was incubated for 5 minutes with 1 ml of a solution containing 50 ^M albumin and 1 U thrombin. The control cultures released 11,800 ± 400 dpm as fatty acid, equivalent to 7.1% of the radioactivity initially contained in the cell lipids. A comparable amount of fatty acid radioactivity was released by the cells previously enriched for 2 hours with arachidonic acid, 11,500 ± 300 dpm, equivalent to 7.2% of the initial lipid radioactivity.
Supplementation with Prostaglandlns
The reason for the failure of arachidonic acid enrichment to enhance PGI 2 production was explored further by determining whether the inhibition was produced by arachidonic acid itself or the prostaglandins formed from it during the supplementation period. To test this, cultures were supplemented with prostaglandins (instead of arachidonic acid) and, after removal of the medium and washing, thrombinstimulated PGI 2 release was measured. An initial incubation for up to 30 minutes with 100 pmol/ml of PGI 2 had no effect on subsequent PGI 2 release in response to thrombin stimulation. In a second experiment, exposure for 10 minutes to 200 pmol/ml PGI 2 also produced no reduction in subsequent thrombin-stimulated PGI 2 release. A similar experiment was done with prostaglandin E, (PGE,) as the supplement, the period of exposure being increased to 4 hours. After incubation with 500 pmol/ml PGE,, the thrombin-stimulated PGI 2 released was reduced only 8% to 10%. Furthermore, in another experiment, exposure for 2 hours to 1 nmol/ml PGE, reduced subsequent thrombin-stimulated PGI 2 release by only 17%.
Recovery of PGI 2 Production
To gain additional insight into the mechanism of inhibition, we determined whether the effect was reversible. In the experiment shown in Figure 4 , thrombin-stimulated PGI 2 release was inhibited by 90% as a result of enrichment with 50 nM supplemental arachidonic acid. Following removal of the supplementation medium and washing, the cells were incubated for up to 18 hours in a medium containing 2.5% fetal bovine serum plus 90 fiM bovine serum albumin. In one set of cultures, 1 ^.g/ml cycloheximide was added. As a control, cultures that were not previously exposed to arachidonic acid were also incubated for up to 18 hours in this medium. The cultures that did not contain cycloheximide progressively recovered the capacity to release PGI 2 , measured by radioim- munoassay as 6-keto-PGF 1n , in response to stimulation for 5 minutes with 1 U/ml thrombin. By 18 hours, they released 97% as much PGI 2 as the corresponding control cells not initially supplemented with arachidonic acid. Recovery was completely inhibited by the presence of cycloheximide. A second experiment indicated that refractory cultures also regained the capacity to produce PGI 2 in response to a 5minute incubation with arachidonic acid and that the recovery of this response followed the same time course as the recovery of thrombin-stimulated PGI 2 release. The concentration of cycloheximide used (1 ^g/ ml) inhibited 3 H-leucine incorporation into cellular proteins by 86%. By contrast, 1 -14 C-palmitic acid incorporation into cellular lipids was not inhibited at either 4 hours or 10 hours and was only inhibited by 28% at 18 hours. No decrease in the protein content of the cultures was detected when they were incubated with 1 /Lig/ml cycloheximide for 18 hours. Therefore, treatment of the confluent cultures with this concentration of cycloheximide inhibited protein synthesis but did not produce a generalized toxic effect.
Enrichment In the Presence of Ibuprofen
When incubation for 24 hours in a medium containing 2.5% fetal bovine serum and 90 nM albumin was carried out in the presence of 50 to 200 /xM ibuprofen, supplementation with 50 fiM arachidonic acid enhanced the capacity of the endothelial cells to release PGI 2 in response to thrombin. This is seen in Figure 5 . In this and subsequent experiments, ibuprofen was removed and the cultures were washed before incubation with thrombin. PGI 2 release was measured by radioimmunoassay as 6-keto-PGF 1a . The enhancement in PGI 2 production by the cells enriched with arachidonic acid increased slightly as the ibuprofen concentration of the supplementation medium was raised, but ibuprofen itself in concentrations up to 200 /AM during the supplementation period had little effect on subsequent thrombin-stimulated PGI 2 release. In this experiment, there was an 80% decrease in PGI 2 production when the supplementation with arachidonic acid was done without ibuprofen.
An additional experiment indicated that 4 hours of arachidonic acid supplementation in the presence of ibuprofen was sufficient to enhance subsequent PGI 2 release in response to thrombin. This enhancement was maintained during the remainder of the 24-hour supplementation period. By contrast, appreciable enhancement did not occur if the supplementation was carried out for only 2 hours. As seen in Figure 6 , near-maximal enhancement in subsequent thrombin-stimulated PGI 2 release was produced by supplementation for 4 hours with 25 ptM arachidonic acid in the presence of 100 /xM ibuprofen. After removal of this medium and washing the cultures, the maximum amount of PGI 2 released in response to a 5-minute exposure to 1 U/ml thrombin was 145 pmol/ml. Much larger amounts of PGI 2 were produced when similarly treated cultures were incubated for the 5-minute period with 200 (JLM arachidonic acid bound to 90 txM albumin instead of thrombin. However, PGI 2 production in response to the added arachidonic acid was not enhanced by prior supplementation with arachidonic acid. An additional experiment (not shown) revealed that the response to external arachidonic acid remained negative when the length of the initial period of supplementation was increased to 20 hours. By contrast, subsequent thrombin-stimulated PGI 2 release was enhanced by 140% to 230% as compared with an unsupplemented control culture when the arachidonic acid supplementation period was 20 hours.
Discussion
These results indicate that human umbilical vein endothelial cells can be enriched with arachidonic acid in such a way that their capacity to release PGI 2 in response to thrombin stimulation is increased. Isotopic studies indicate that almost 50% of the arachidonic acid taken up by the cells accumulates in the choline and inositol phosphoglycerides, phospholipids that are reported 24 " 26 to provide the substrate for thrombin-stimulated prostagiandin production. As opposed to the enhanced response to thrombin stimulation, the cultures supplemented with arachidonic acid did not exhibit increased PGI 2 production when they were subsequently incubated with high concentrations of arachidonic acid. This suggests that the enzymatic machinery for conversion of arachidonic acid to PGI 2 is not activated by the process of supplementation. Rather, it appears that the mechanism of the enhancement involves an enrichment of the intracellular phospholipid pools which are then able to release more arachidonic acid when prostagiandin production is stimulated.
In order to enhance the capacity of the cells to produce PGI 2 , it was necessary to enrich the cultures in the presence of ibuprofen, a reversible cyclooxygenase inhibitor. 2223 This prevented PGI 2 formation during supplementation. When the cultures were enriched with arachidonic acid in the absence of ibuprofen, the release of arachidonic acid in response to thrombin stimulation was not reduced. This indicates that the decrease in PGI 2 production is not due to inhibition of the enzymes that release arachidonic acid from the intracellular phospholipid storage pools. Therefore, it appears that the enzymatic pathway which converts arachidonic acid to PGI 2 is inhibited when the cultures are enriched in the absence of ibuprofen. The inability of these cultures to form PGI 2 from extracellular arachidonic acid also is consistent with a mechanism involving inhibition of one or more of the enzymes that synthesize PGI 2 .
The inactivation that occurs when the cells are enriched with arachidonic acid in the absence of ibuprofen could be due to feedback inhibition caused by the PGI 2 that is formed, 27 ' M but such a mechanism is unlikely because PGI 2 production was not inactivated when the cultures were supplemented with either PGI 2 or PGE 2 instead of arachidonic acid. This result is not conclusive, however, because the inhibitory effect could be specific for PGI 2 , and the added PGI 2 might have been inactivated too rapidly to produce feedback inhibition. While this is possible in view of the very short half-life of PGI 2 , it is unlikely because the PGI 2 was added together with albumin. Previous work 29 has shown that albumin protects PGI 2 against rapid inactivation. In this regard, Brotherton, et al. 30 have recently shown that increasing the cyclic AMP content of endothelial cells by the addition of either PGI 2 or forskolin does not inhibit subsequent PGI 2 production in response to a suitable stimulus. These findings also are not consistent with a feedback inhibition mechanism. Furthermore, Brotherton and Hoak 31 have demonstrated that prostagiandin H 2 conversion to PGI 2 is not inhibited by previous exposure of the endothelial cells to substances that stimu-late PGI 2 production, including arachidonic acid. Therefore, it is unlikely that the inhibition observed in the present work involves prostacyclin synthetase. An alternative possibility is that cyclooxygenase becomes inactivated as it operates during the supplementation period. Such an explanation is consistent with previous reports that cyclooxygenase is inactivated during catalysis, apparently by a hydroperoxide generated in the reaction. 32~35 It is also consistent with the observation that 15-hydroperoxyarachidonic acid inhibits prostacyclin synthesis in calf aortic endothelial cells. 36 As opposed to these findings with endothelial cells, enrichment of 3T3 cells with arachidonic acid did not inhibit subsequent prostagiandin production even though the supplementation was carried out in the absence of any cyclooxygenase inhibitor. 6 Therefore, the inhibition that occurs with endothelial cells is not a response exhibited by all cultured cells. As opposed to endothelial cells, 3T3 cells release only a relatively small amount of PGI 2 ; their main prostagiandin product is PGE 2 . 63738 Although this could be a reason for the observed difference, it is unlikely because conversion of 1 J4 C-arachidonic acid to PGE 2 and PGF 2a was also reduced when endothelial cultures were enriched with arachidonic acid in the absence of ibuprofen. The fact that the reduction is not confined to PGI 2 is consistent with the possibility that the inhibition involves the cyclooxygenase reaction. Such control may provide the endothelium with a regulatory mechanism that prevents continuous or excessive PGI 2 production, helping to provide a balance between factors to promote and prevent blood coagulation.
